Dementia Discovery Fund
VC Fund
London, United Kingdom
Dementia Discovery Fund is a VC fund in London focused on Biotechnology and Health Care. The Dementia Discovery Fund is the world’s largest venture fund focused entirely on discovering and developing novel therapies for dementia, including Alzheimer’s disease.The DDF has raised a total of £250 million to develop novel disease-modifying therapeutics for all forms of dementia.They have a mandate to validate novel hypotheses andexpand the breadth of targets and mechanisms in development for dementia over the 15 year life of the fund.This enables the DDF to invest in truly novel, early-stage projects starting from target identification, and explore novel biological insights for translation into disease-modifying drugs.
- Total investments:
- 56
- Last investment:
- Lead investor:
- 39%
- Fund size:
- $269M
- Last fund:
Last updated:
For AI agents: llms.txt
Industries Dementia Discovery Fund invests in
Stages Dementia Discovery Fund invests in
Countries Dementia Discovery Fund invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
| See all 9 contacts → | |||
Round size
- Seed
- $4.8M–$20M
- Series A
- $7M–$78M
- Venture - Series Unknown
- $1.6M–$48M
Investment Focus
Industry
- Biotechnology 21 (38%)
- Health Care 13 (23%)
- Therapeutics 13 (23%)
- Medical 8 (14%)
- Life Science 6 (11%)
Stage
- Seed 13 (23%)
- Series A 12 (21%)
- Venture - Series Unknown 6 (11%)
- Series B 5 (9%)
- Funding Round 2 (4%)
Country
- United States 17 (30%)
- United Kingdom 11 (20%)
- Israel 1 (2%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Angus Grant
Chief Executive Officer
|
Chief Executive Officer | Total investments: 0 | Find email | |
Barbara Tate
Chief Strategy Officer
|
Chief Strategy Officer | Total investments: 0 | Find email | |
Jonathan Behr
Partner
|
Partner | Total investments: 9 | Find email | |
Jonathan Behr
Partner
|
Partner | Total investments: 0 | Find email | |
Damian Crowther
Entrepreneur In Residence
|
Entrepreneur In Residence | Total investments: 0 | Find email | |
| See all 9 team members → | ||||
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Leal Therapeutics develops novel therapeutics for patients. | $30M / Series A / Aug 17, 2026 | ||
| TRIMTECH Therapeutics is a biotech organization that treats neurodegenerative illnesses by using targeted protein degradation (TPD). | $14M / Seed / Jun 23, 2026 | ||
| Violet Therapeutics is a healthcare company that operates in stealth mode. | $4.8M / Seed / May 13, 2026 | ||
| Cerevance is a biotechnology company that develops novel therapeutics for neurological diseases, including chronic neurodegenerative conditions such as Alzheimer's disease, Parkinson's disease, frontotemporal dementia, and amyotrophic lateral sclerosis. Using a large and growing repository of over 15,000 human brain tissue samples, thecompany generates an unprecedented level of expression and epigenetic data, enabling the company to identify the most promising targets for the next generation of treatments for CNS disorders. | $20M / Series C / May 12, 2026 | ||
| ndLyz Therapeutics, Inc. is developing disease-modifying therapeutics which restore endo-lysosomal function and abrogate neurodegeneration in Parkinson’s disease (PD) and other dementias. | $17.3M / Seed / Apr 23, 2026 | ||
| NRG Therapeutics is a drug discovery company focussed on therapeutic approaches that will restore mitochondrial function and slow or halt the progression of neurodegenerative diseases such as Parkinson’s disease, Alzheimer’s disease and motor neurone disease. Founded in 2018 by a team of experienced biotech and pharmaceutical industryprofessionals, with a background in neuroscience drug discovery, NRG Therapeutics will initially focus on the discovery and development of brain penetrant mitochondrial permeability transition pore inhibitors for the treatment of Parkinson’s disease. | $67.8M / Series B / Sep 08, 2025 | ||
| Leal Therapeutics develops novel therapeutics for patients. | $30M / Series A / Aug 27, 2025 | ||
| Therini Bio is dedicated to the research and development of novel therapeutics for the treatment of neurological diseases. The company's approach is based on novel findings by the Akassoglou lab at Gladstone/UCSF that implicate fibrin as a key driver of neuroinflammation. | $39M / Series A / May 14, 2025 | ||
| Montara Therapeutics is a biotechnology company. | $20M / Seed / Mar 13, 2025 | ||
| TRIMTECH Therapeutics is a biotech organization that treats neurodegenerative illnesses by using targeted protein degradation (TPD). | $31M / Seed / Mar 05, 2025 | ||
| See all 56 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Dementia Discovery Fund invest in?
Dementia Discovery Fund invests primarily in Biotechnology, Health Care and Therapeutics startups, most often at Seed and Series A stage. Most of the 56 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Dementia Discovery Fund's check size?
Dementia Discovery Fund typically joins rounds of $4.8M–$20M at Seed, $7M–$78M at Series A and $1.6M–$48M at Venture - Series Unknown. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Dementia Discovery Fund participates in.
How do I contact Dementia Discovery Fund?
Public channels for Dementia Discovery Fund include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Dementia Discovery Fund?
The team at Dementia Discovery Fund includes Angus Grant (Chief Executive Officer), Barbara Tate (Chief Strategy Officer) and Jonathan Behr (Partner), among 9 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
